This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
by Zacks Equity Research
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
by Zacks Equity Research
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
What Makes Immunovant (IMVT) a New Buy Stock
by Zacks Equity Research
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
by Zacks Equity Research
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Immunovant, Inc. (IMVT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data
by Zacks Equity Research
Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
by Zacks Equity Research
Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
by Zacks Equity Research
Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
by Zacks Equity Research
Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
by Zacks Equity Research
Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.
Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
by Zacks Equity Research
Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.